Abnormal tumor markers
ICD-10 R97 is a billable code used to indicate a diagnosis of abnormal tumor markers.
Abnormal tumor markers refer to elevated or altered levels of specific substances in the blood that may indicate the presence of cancer or other diseases. These markers are typically proteins produced by cancer cells or by the body in response to cancer. Common tumor markers include prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and cancer antigen 125 (CA-125). The presence of abnormal levels of these markers can aid in the diagnosis, monitoring, and management of various malignancies. However, it is important to note that elevated tumor markers are not definitive for cancer and can be influenced by other conditions, such as benign tumors, infections, or inflammatory diseases. Therefore, abnormal tumor marker results should be interpreted in conjunction with clinical findings, imaging studies, and histopathological evaluations to establish a comprehensive diagnosis.
Clear documentation of the clinical rationale for testing tumor markers, including patient history and presenting symptoms.
Routine screening for cancer in high-risk patients, monitoring treatment response in known malignancies.
Ensure that the abnormal results are linked to a specific diagnosis or condition to avoid coding errors.
Immediate documentation of abnormal lab results and their clinical implications, including any acute symptoms.
Patients presenting with acute symptoms suggestive of malignancy or complications from known cancers.
Rapid assessment and documentation are crucial; ensure that abnormal findings are communicated effectively.
Used for monitoring prostate cancer patients.
Document the reason for the PSA test and any relevant clinical history.
Urology practices should ensure thorough documentation of patient history and follow-up plans.
Tumor markers are substances found in the blood, urine, or tissues that can be elevated in the presence of cancer. They are used to help diagnose, monitor treatment, and assess prognosis.
Yes, elevated tumor markers can also be associated with benign conditions, infections, or inflammatory diseases, which is why they must be interpreted in the context of the patient's overall clinical picture.
